Venture funding slowdown continues in first quarter of 2019
Venture funding drops again, but there’s no need to panic yet.
Upcoming events – Novo takes aim at type 1 diabetes and Aslan wants to roar
Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
Déjà vu for Aveo and tivozanib
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
Sillajen and Transgene bid to revive the oncolytic virus craze
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
AACR 2019 – Foundation Medicine sets the scene for liquid biopsy approval
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
AACR 2019 – Rubraca trial points to a place for Parps in pancreatic cancer
Encouraging early data from an academic trial of Clovis's Rubraca raise hopes that Parps could emerge as a more tolerable maintenance therapy for some pancreatic…
AACR 2019 – Entinostat turns Syndax’s frown upside down
After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.
AACR 2019 – Xospata meets the conditions of its US approval
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
AACR 2019 – Guardant looks to its other liquid biopsy
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.